MCID: ESP023
MIFTS: 53

Esophageal Disease

Categories: Gastrointestinal diseases, Oral diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Esophageal Disease

MalaCards integrated aliases for Esophageal Disease:

Name: Esophageal Disease 11 14 16 75
Esophageal Diseases 53 43 71
Esophageal Disorder 75
Ulcer of Esophagus 71
Esophageal Ulcer 11

Classifications:



External Ids:

Disease Ontology 11 DOID:6050
ICD9CM 34 530.9
MeSH 43 D004935
NCIt 49 C3027
SNOMED-CT 68 266497000
ICD10 31 K22.1 K22.9
UMLS 71 C0014852 C0151970

Summaries for Esophageal Disease

Disease Ontology: 11 A gastrointestinal system disease that is located in the esophagus.

MalaCards based summary: Esophageal Disease, also known as esophageal diseases, is related to barrett esophagus and esophagus adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Esophageal Disease is CEACAM5 (CEA Cell Adhesion Molecule 5), and among its related pathways/superpathways are miRNAs involvement in the immune response in sepsis and Cell differentiation - expanded index. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include esophagus, trachea and heart.

Wikipedia 75 Esophageal disease: Esophageal diseases can derive from congenital conditions, or they can be acquired later in... more...

Esophageal disorder: The esophagus (American English) or oesophagus (British English; both /iːˈsɒfəɡəs, ɪ-/), non-technically... more...

Related Diseases for Esophageal Disease

Diseases related to Esophageal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 475)
# Related Disease Score Top Affiliating Genes
1 barrett esophagus 31.7 MIR196A1 ATP4A ATP12A
2 esophagus adenocarcinoma 31.1 MIR21 MIR199A1 MIR196A1 MIR145 MIR143 ATP4A
3 esophagitis, eosinophilic, 1 31.0 MIR21 CCR6 ATP4A ATP12A
4 peptic esophagitis 31.0 CCR6 ATP4A ATP12A
5 esophageal candidiasis 30.9 CCR6 ATP4A ATP12A
6 esophageal cancer 30.9 MIR486-1 MIR338 MIR223 MIR21 MIR199A1 MIR196A1
7 immune deficiency disease 30.7 MIR223 MIR21 MIR199A1 MIR196A1 MIR17 MIR144
8 lymphoma, hodgkin, classic 30.5 MIR21 MIR140 KDM4C CCR6
9 aortic aneurysm, familial abdominal, 1 30.5 MIR21 MIR199A1 MIR144 CCR6
10 hypertrophic cardiomyopathy 30.4 MIR486-1 MIR223 MIR21 MIR199A1 MIR17 MIR140
11 myeloma, multiple 30.4 MIR21 MIR199A1 MIR17 MIR145 MIR140 MIR106B
12 myocardial infarction 30.4 MIR486-1 MIR223 MIR21 MIR199A1 MIR17 MIR145
13 rectal benign neoplasm 30.4 MIR17 MIR145 MIR143 CEACAM5
14 viral esophagitis 30.3 ATP4A ATP12A
15 lung disease 30.3 MIR21 MIR199A1 MIR17 MIR145 CEACAM5 CCR6
16 multiple endocrine neoplasia, type i 30.3 MIR21 MIR139 ATP4A ATP12A
17 alcohol use disorder 30.3 MIR199A1 MIR196A1 KDM4C CCR6 ATP12A
18 atrophic gastritis 30.3 MIR196A1 ATP4A ATP12A
19 leukemia, chronic lymphocytic 30.3 MIR486-1 MIR338 MIR223 MIR21 MIR199A1 MIR196A1
20 peptic ulcer disease 30.3 CCR6 ATP4A ATP12A
21 cervical cancer 30.3 MIR338 MIR21 MIR196A1 MIR17 MIR149 MIR143
22 peptic ulcer perforation 30.3 ATP4A ATP12A
23 mediastinitis 30.3 ATP4A ATP12A
24 connective tissue disease 30.3 MIR486-1 MIR338 MIR223 MIR21 MIR199A1 MIR196A1
25 rectum cancer 30.3 MIR338 MIR21 MIR17 MIR145 MIR144 MIR143
26 interstitial lung disease 2 30.2 MIR486-1 MIR338 MIR21 MIR199A1 MIR196A1 MIR17
27 lipoprotein quantitative trait locus 30.2 MIR486-1 MIR223 MIR21 MIR199A1 MIR17 MIR145
28 squamous cell carcinoma, head and neck 30.2 MIR486-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR149
29 head and neck cancer 30.1 MIR486-1 MIR338 MIR21 MIR199A1 MIR196A1 MIR17
30 megaesophagus 30.1 ATP4A ATP12A
31 meckel diverticulum 30.1 ATP4A ATP12A
32 gastrointestinal system disease 30.0 MIR486-1 MIR338 MIR223 MIR21 MIR199A1 MIR196A1
33 genetic gastro-esophageal disease 11.0
34 achalasia 11.0
35 zollinger-ellison syndrome 10.9
36 cervix small cell carcinoma 10.6 MIR199A1 MIR145 MIR143 MIR10B
37 pancreatic vasoactive intestinal peptide producing tumor 10.6 ATP4A ATP12A
38 acquired laryngomalacia 10.6 ATP4A ATP12A
39 internal hemorrhoid 10.6 CEACAM5 ATP4A ATP12A
40 hemorrhoid 10.6 CEACAM5 ATP4A ATP12A
41 glioma 10.6 MIR21 MIR17 MIR140 MIR10B
42 autoimmune pancreatitis 10.6 MIR21 CEACAM5 CCR6
43 squamous papillomatosis 10.6 CEACAM5 ATP4A ATP12A
44 esophageal tuberculosis 10.6 CEACAM5 ATP4A ATP12A
45 duodenal obstruction 10.6 CEACAM5 ATP4A ATP12A
46 acute cholangitis 10.6 CEACAM5 ATP4A ATP12A
47 abdominal tuberculosis 10.6 CEACAM5 ATP4A ATP12A
48 common bile duct disease 10.6 MIR145 CEACAM5 ATP4A ATP12A
49 interstitial lung disease 10.6 MIR223 MIR21 MIR199A1 CCR6
50 scalp dermatosis 10.6 ATP4A ATP12A

Comorbidity relations with Esophageal Disease via Phenotypic Disease Network (PDN): (show all 25)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Bronchitis
Chronic Kidney Disease Decubitus Ulcer
Deficiency Anemia Duodenitis
Dyskinesia of Esophagus Esophageal Cancer
Esophageal Candidiasis Esophageal Varix
Esophagitis Esophagus Carcinoma in Situ
Heart Disease Hypertension, Essential
Intestinal Obstruction Iron Deficiency Anemia
Mallory-Weiss Syndrome Megaesophagus
Paralytic Ileus Peptic Esophagitis
Protein-Energy Malnutrition Schizophreniform Disorder
Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Disease:



Diseases related to Esophageal Disease

Symptoms & Phenotypes for Esophageal Disease

UMLS symptoms related to Esophageal Disease:


nausea and vomiting; constipation; abdominal pain; diarrhea; tinnitus; snoring; dyspepsia; sore throat; icterus; signs and symptoms, digestive; coughing; vertigo/dizziness; equilibration disorder; heartburn; gastrointestinal gas; digestive system symptom

Drugs & Therapeutics for Esophageal Disease

Drugs for Esophageal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Methylnaltrexone Approved Phase 4 916055-93-1 5361918
7
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
8
Remifentanil Approved Phase 4 132875-61-7 60815
9
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
10
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
12 Gastrointestinal Agents Phase 4
13 Neuroprotective Agents Phase 4
14 Antiemetics Phase 4
15
Methylprednisolone Acetate Phase 4 584547
16 Pharmaceutical Solutions Phase 4
17 Analgesics, Opioid Phase 4
18 Narcotic Antagonists Phase 4
19 Narcotics Phase 4
20 Dopamine Antagonists Phase 4
21 Dopamine Agents Phase 4
22
Pantoprazole Approved Phase 3 102625-70-7, 138786-67-1 4679
23
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
24
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
25
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
26
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
27
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
28
Rabeprazole Approved, Investigational Phase 2 117976-89-3, 117976-90-6 5029
29
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
30
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
31
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
32
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
33
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
34
Fluorouracil Approved Phase 2 51-21-8 3385
35
Naloxegol Approved Phase 2 854601-70-0 75040638 56959087
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
37
Nimotuzumab Investigational Phase 2 780758-10-3
38 Immunoglobulins Phase 2
39 Antibodies Phase 2
40 Anti-Infective Agents Phase 2
41 Antifungal Agents Phase 2
42
Hydroxyitraconazole Phase 2 108222
43 Cytochrome P-450 Enzyme Inhibitors Phase 2
44 Cytochrome P-450 CYP3A Inhibitors Phase 2
45 Folate Phase 2
46 Vitamin B9 Phase 2
47 Anti-Ulcer Agents Phase 2
48 Antacids Phase 2
49 Antimitotic Agents Phase 2
50 Tubulin Modulators Phase 2

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
2 High Doses of Methylprednisolone in the Management of Caustic Esophageal Burns in Children Completed NCT02002078 Phase 4 methylprednisolon
3 Is the Opioid-induced Pharyngeal and Esophageal Dysfunction Peripherally or Central Mediated? Completed NCT01012960 Phase 4 methylnaltrexone
4 Can Opioid Induced Effects on Esophageal Motility and Lower Esophageal Sphincter be Counteracted by a Dopamine Receptor Antagonist? Completed NCT01191645 Phase 4 naloxone;remifentanil;Sodium Chloride;metoclopramide
5 Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain Withdrawn NCT02569073 Phase 4 Dronabinol;Placebo
6 Treatment Response of High-dose and Standard-dose Rabeprazole for Gastroesophageal Reflux Disease With Extra-esophageal Manifestations: a Single-center, Randomized, Open-label Trial. Completed NCT04001400 Phase 3 Rabeprazole 20mg bid;Rabeprazole 20mg qd
7 Efficacy of DA-5204 (Stillen 2X®) for Patients With Gastroesophageal Reflux Disease: A Randomized, Double-blind, Placebo-controlled Pilot Study Completed NCT03998969 Phase 3 Pantoprazole;DA-5204;Placebo
8 Phase II Study of Radiation Therapy With Peptide Specific CTL Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer Unknown status NCT03011255 Phase 2
9 Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma Unknown status NCT03200691 Phase 2 anti-PD-1 antibody SHR-1210
10 Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer Completed NCT03187314 Phase 2 Radiation;SHR-1210
11 Phase II Study of Concurrent Chemoradiotherapy With Itraconazole in Treating Patients With Locally Advanced Esophageal Squamous Cancer Recruiting NCT04481100 Phase 2 itraconazole
12 Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial. Recruiting NCT03549494 Phase 2
13 A Prospective, Open-label Clinical Study on the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With Camrelizumab Combined With Chemoradiotherapy Not yet recruiting NCT05624099 Phase 2 Camrelizumab;Paclitaxel;Platinum
14 A Multicenter, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Controlled Phase II Clinical Trial to Evaluate Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis Not yet recruiting NCT05604261 Phase 2 Anaprazole sodium 40 mg;Anaprazole sodium 60 mg;Rabeprazole sodium 20 mg
15 An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients as Postoperative Adjuvant Therapy Not yet recruiting NCT05252078 Phase 2 Anlotinib hydrochloride;TQB2450
16 A Phase II Trial of Erlotinib and Avastin in Previously Treated Patients With Cancer of the Esophagus or Gastroesophageal Junction Terminated NCT00442507 Phase 2 Erlotinib;Avastin
17 Phase II Study of Pre-Operative Chemotherapy With Taxol, Cisplatin, and 5-Fluorouracil Followed by G-CSF in Patients With Resectable Local-Regional Carcinoma of Esophagus Terminated NCT00208936 Phase 2 Taxol, Cisplatin, 5-Fluorouracil, G-CSF
18 Movantik for Opioid-Related Esophageal Disorders Terminated NCT02998606 Phase 2 Naloxegol;Placebo Oral Capsule
19 Prospective Study of the Effects of Non-dependent Lung High Frequency Positive Pressure Ventilation on the Right Ventricular Function for Thoracotomy Completed NCT01019993 Phase 1
20 Perioperative Versus Preoperative Chemotherapy With Surgery in Patients With Locoregional Squamous Carcinoma of Esophagus Completed NCT01225523 Phase 1 Paclitaxel; Cisplatin; 5-Fluorouracil;Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine
21 A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology Active, not recruiting NCT03330028 Phase 1 Dexamethasone;Diphenhydramine;Famotidine;Mitomycin C;Cisplatin;Paclitaxel
22 The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity in Healthy Volunteers Unknown status NCT02620176
23 Evaluation of Esophageal Damage During Conventional Pulmonary Vein Ablation Procedures and Potential Strategies to Protect the Esophagus. Pilot Study. Unknown status NCT03832959
24 Oesophageal Protection: a Novel Approach to Improving the Safety of Catheter Ablation for Atrial Fibrillation. Unknown status NCT03819946
25 Indications and Outcomes of Gastrointestinal Endoscopic Ultrasound in Tanta-Egypt: Initial Experience. Unknown status NCT03267355
26 Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index: A Prospective Multicenter Study Unknown status NCT00939263
27 Endosonography-Guided Fine-Needle-Aspiration (EUS-FNA) Versus Key Hole Biopsy (KHB) in Diagnostics of Upper Gastrointestinal Submucosal Tumors - a Randomized Trial Unknown status NCT02025244
28 Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter in Patients With Spastic Esophageal Disorders Such as Achalasia Unknown status NCT02425033
29 Radiofrequency Ablation for the Treatment of Large Symptomatic Heterotopic Gastric Mucosa - a Prospective Randomized Sham-controlled Trial - the RAGE Study Unknown status NCT03518905
30 Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound and Interventional Endoscopy in Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Unknown status NCT01438385
31 Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux Completed NCT00584259
32 Factors Linked to Outcomes After Esophageal Cancer Surgery: a Multicenter National Study Completed NCT01927016
33 Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses Completed NCT02105506 Tachosil patch
34 A Novel Disposable Transnasal Esophagoscope: a Prospective Pilot Trial of Feasibility, Safety and Tolerance Completed NCT01360515
35 The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy Completed NCT03859557
36 Esophageal Squamous Cell Carcinoma African Prevention Research (ESCCAPE) Cytosponge™ Feasibility Study Completed NCT04090554
37 Drop in Gastroscopy - Experience After 9 Months Completed NCT00977678
38 The Role of Endoscopic Confocal Microscopy in Diagnosing Colorectal Cancer and Other Gastrointestinal Pathologies in Vivo Completed NCT00874263
39 Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders Completed NCT02476513
40 Progenitor Cells in Human Esophagus Completed NCT03108898
41 EndoVE endosCopic Treatment for Oesophageal and Gastric canceR Completed NCT04649372
42 Impact of Antibiotic Prophylaxis and Conditioning Modalities in Per Oral Endoscopic Myotomy for Esophageal Motor Disorders Completed NCT03944863 Antibiotics
43 A Prospective Randomized Study on the Effect of Oesophageal Temperature Monitoring on the Incidence of Esophageal Lesions After Left Atrial Ablation for the Treatment of Atrial Fibrillation. Completed NCT03645070
44 National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base Recruiting NCT02526095
45 Accuracy of Detachable String Magnetically Controlled Capsule Endoscopy for Follow-up of Patients With Esophageal Diseases: A Multicenter Study Recruiting NCT05469152
46 Feasibility and Safety of Ultrasound Capsule Endoscopy for Esophagus Examination:a Pilot Study Recruiting NCT05054933
47 CDx Study 906: The Clinical Utility of WATS3D (Wide Area Transepithelial Sampling With Computer-Assisted 3-Dimensional Analysis): A 5- Year Prospective Registry Recruiting NCT04312633
48 The WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) U.S. Registry Recruiting NCT02988934
49 Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered Recruiting NCT05182255
50 The Strategy of Implementation of the ERAS Protocol After Esophageal Surgery Based on Innovative Technologies Recruiting NCT05311787

Search NIH Clinical Center for Esophageal Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lidocaine
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
LIDOCAINE PWDR

Cochrane evidence based reviews: esophageal diseases

Genetic Tests for Esophageal Disease

Anatomical Context for Esophageal Disease

Organs/tissues related to Esophageal Disease:

FMA: Esophagus
MalaCards : Trachea, Heart, Lung, Lymph Node, Colon, Breast, Bone Marrow

Publications for Esophageal Disease

Articles related to Esophageal Disease:

(show top 50) (show all 1734)
# Title Authors PMID Year
1
Detection of occult lymph node metastases in esophageal cancer by minimally invasive staging combined with molecular diagnostic techniques. 53 62
10036123 1998
2
Endoscopic Submucosal Dissection in the Esophagus: Indications, Techniques, and Outcomes. 62
36375886 2023
3
Surgery for mesenchymal neoplasms of the esophagus: experience over 2 decades from a tertiary healthcare center in India. 62
36149582 2022
4
MitraClip procedure assisted with 3-dimensional electro anatomical mapping system. 62
36187317 2022
5
Point-of-care ultrasound in the head and neck region. 62
36284028 2022
6
Advanced Endoscopy for Benign Esophageal Disease: A Review Focused on Non-Erosive Reflux Disease and Eosinophilic Esophagitis. 62
36360524 2022
7
Mapping the adult human esophagus in vivo and in vitro. 62
36278875 2022
8
Same-Day Home Recovery After Surgery for Benign Esophageal Diseases-Is It Really Good for Patients? 62
36103162 2022
9
Development of Bio-artificial Esophageal Tissue Engineering Utilization for Circumferential Lesion Transplantation: A Narrative Review. 62
36117582 2022
10
The Utility of Myositis Specific Antibodies in Clinical Practice. 62
35716140 2022
11
First Therapeutic Approval for Eosinophilic Esophagitis. 62
35967984 2022
12
Eosinophilic esophagitis due to aeroallergens: A Systematic Review, update, and our experience. 62
36000828 2022
13
Esophageal disease and loss to follow-up are common among patients who experience non-endoscopic resolution of food impaction. 62
35938855 2022
14
Proteomic profiling of plasma exosomes reveals CD82 involvement in the development of esophageal squamous cell carcinoma. 62
35728771 2022
15
Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases. 62
34213831 2022
16
The relationship between gastroesophageal reflux disease and autism spectrum disorder in adult patients in the United States. 62
34859933 2022
17
Eosinophilic Esophagitis in Esophageal Atresia: Is It Really a New Disease? 62
35884016 2022
18
A 44-year-old man with esophageal ulcer. 62
35865767 2022
19
Syphilis in the Esophagus. 62
35765682 2022
20
Poly(lactic acid)-hyperbranched polyglycerol nanoparticles enhance bioadhesive treatment of esophageal disease and reduce systemic drug exposure. 62
35639565 2022
21
Effect of intracordal injection under local anesthesia on vital signs in high-risk patients. 62
34711470 2022
22
Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission. 62
35304158 2022
23
Fluorescence-Guided Thoracic Duct Dissection in Robotic en Bloc Esophagectomy. 62
34560041 2022
24
Chitosan/collagen layer-by-layer deposition for improving the esophageal regeneration ability of nanofibrous mats. 62
35337499 2022
25
Model for multi-disciplinary, multi-institutional virtual learning: The Stanford Esophageal Virtual Collaborative Conference on benign esophageal diseases. 62
35340088 2022
26
[Robotic-assisted Thoracic Surgery]. 62
35728590 2022
27
The true prevalence of cervical inlet patch in a specific center dealing with esophageal diseases. 62
35587062 2022
28
Update on the Diagnosis and Treatment of Achalasia. 62
35585208 2022
29
Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. 62
35085819 2022
30
Esophageal achalasia: An unusual reason for lung abscess. 62
35509343 2022
31
Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report. 62
34263613 2022
32
[Upper gastrointestinal ulcer in children: a clinical analysis of 173 cases]. 62
35527410 2022
33
AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. 62
35183361 2022
34
Identification of tissue-specific microbial profile of esophageal squamous cell carcinoma by full-length 16S rDNA sequencing. 62
35435458 2022
35
A Case of Heterotopic Gastric Tissue in Duodenal Bulb: An Interesting Endoscopic Finding. 62
35607542 2022
36
Physiological and Pathological Significance of Esophageal TRP Channels: Special Focus on TRPV4 in Esophageal Epithelial Cells. 62
35562940 2022
37
Expression of Adhesion Molecules in a Gastroduodenal Reflux Murine Model. 62
33774002 2022
38
Pharmacotherapies in eosinophilic esophagitis: state of the art. 62
35302339 2022
39
[Diagnosis and Treatment of Eosinophilic Esophagitis]. 62
35342167 2022
40
The challenges of drug delivery to the esophagus and how to overcome them. 62
35062853 2022
41
Validation of the Short-Form Esophageal Hypervigilance and Anxiety Scale. 62
33348046 2022
42
Dietary patterns and severity of symptom with the risk of esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional latent class analysis. 62
35062901 2022
43
Development and Prospect of Esophageal Tissue Engineering. 62
35252159 2022
44
Esophageal cancer and bacterial part of gut microbiota - A multidisciplinary point of view. 62
36467733 2022
45
Noninvasive Detection of Esophageal Cancer by the Combination of mSEPT9 and SNCG. 62
35089073 2022
46
Establishment of a Dissolution Test System for the Biorelevant Characterization of Esophageal Applied Dosage Forms. 62
34102203 2022
47
Venous thromboembolism in benign esophageal surgery patients: potential cost effectiveness of Caprini risk stratification. 62
33492505 2022
48
Commentary: Choosing the Right Model for Bile Reflux Induced Esophageal Disease Research. 62
34525392 2022
49
Esophagitis Dissecans Superficialis: A Frequently Missed and Rarely Reported Diagnosis. 62
35233324 2022
50
Demystifying Esophageal Lichen Planus: A Comprehensive Review of a Rare Disease You Will See in Practice. 62
34591036 2022

Variations for Esophageal Disease

Expression for Esophageal Disease

Search GEO for disease gene expression data for Esophageal Disease.

Pathways for Esophageal Disease

Pathways related to Esophageal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.35 MIR21 MIR199A1 MIR149 MIR145 MIR106B
2
Show member pathways
11.33 MIR486-1 MIR223 MIR199A1 MIR17 MIR145 MIR143
3 10.93 MIR223 MIR21 MIR17 MIR145 MIR143 MIR106B

GO Terms for Esophageal Disease

Cellular components related to Esophageal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 MIR486-1 MIR338 MIR223 MIR21 MIR199A1 MIR17
2 RISC complex GO:0016442 9.8 MIR106B MIR10B MIR139 MIR140 MIR143 MIR144

Biological processes related to Esophageal Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell migration GO:0030336 9.91 MIR338 MIR21 MIR149 MIR145
2 negative regulation of inflammatory response GO:0050728 9.87 MIR223 MIR199A1 MIR149 MIR145
3 negative regulation of angiogenesis GO:0016525 9.84 MIR21 MIR145 MIR143 MIR106B
4 negative regulation of gene expression GO:0010629 9.8 MIR338 MIR21 MIR199A1 MIR17 MIR144 MIR140
5 miRNA-mediated gene silencing GO:0035195 9.75 MIR106B MIR10B MIR139 MIR140 MIR143 MIR144
6 negative regulation of epithelial to mesenchymal transition GO:0010719 9.73 MIR149 MIR145 MIR144
7 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.72 MIR149 MIR21 MIR223
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.69 MIR199A1 MIR196A1 MIR149
9 angiotensin-activated signaling pathway GO:0038166 9.61 MIR145 MIR143
10 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR223 MIR21 MIR140
11 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.6 MIR199A1 MIR17
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR21 MIR17
13 aorta smooth muscle tissue morphogenesis GO:0060414 9.58 MIR145 MIR143
14 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
15 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.58 MIR486-1 MIR223 MIR140
16 negative regulation of vascular endothelial growth factor production GO:1904046 9.54 MIR140 MIR17 MIR199A1
17 negative regulation of BMP secretion GO:2001285 9.52 MIR17 MIR140
18 regulation of phenotypic switching GO:1900239 9.49 MIR145 MIR143
19 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.48 MIR17 MIR143
20 positive regulation of cellular response to hypoxia GO:1900039 9.46 MIR21 MIR145
21 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.46 MIR21 MIR199A1 MIR145 MIR106B
22 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.43 MIR21 MIR17 MIR145 MIR144 MIR10B MIR106B
23 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR145 MIR143

Molecular functions related to Esophageal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.77 MIR486-1 MIR338 MIR223 MIR21 MIR199A1 MIR17
2 P-type sodium:potassium-exchanging transporter activity GO:0005391 9.62 ATP4A ATP12A
3 mRNA base-pairing translational repressor activity GO:1903231 9.5 MIR486-1 MIR338 MIR223 MIR21 MIR199A1 MIR196A1
4 P-type potassium:proton transporter activity GO:0008900 9.46 ATP4A ATP12A
5 P-type potassium transmembrane transporter activity GO:0008556 9.26 ATP4A ATP12A

Sources for Esophageal Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....